July 18, 2018

BONESUPPORT appoints Michael Diefenbeck as Head of Research & Development, Medical and Clinical Affairs

Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONE...
Read more
July 18, 2018

Cash position and activity update for H1 2018 and key perspectives for the end of 2018

  Solid cash position of €13.5 million at June 30, 2018 Key highlights of H1 2018: primary objective met in the first results of TARGET PHASE II study and with...
Read more
July 13, 2018

HealthCap makes 112th investment as Swedish company Modus Therapeutics completes SEK 140 million financing led by HealthCap

Funds to be used to continue the clinical development of sevuparin for sickle cell disease STOCKHOLM, SWEDEN – 13 July 2018: Modus Therapeutics AB, a company developing innovati...
Read more
July 12, 2018

Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors

GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today ...
Read more
July 12, 2018

Targovax and SOTIO announce first patient dosed in Phase I/II combination trial of ONCOS-102 with DCVAC

Oslo, Norway, 12 July 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing and commercializing immune activators to target hard to treat solid tumors, an...
Read more
July 12, 2018

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors

AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PA...
Read more
July 12, 2018

Interim Report Q2 2018

Zubsolv® continues its strong performance Q2 2018 highlights Total net revenues of SEK 199.7 million (159.1), up 25.5 percent from Q2 previous year Zubsolv US net reven...
Read more
July 11, 2018

Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer

GAITHERSBURG, Md., July 10, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on infectious disease, today announced it has...
Read more
July 5, 2018

Håkan Johansson to start as BONESUPPORT’s CFO at the end of 2018

Lund, Sweden, 18:00 CET, July 4 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that a...
Read more
July 3, 2018

Vicore Pharma and HealthCap create a leading drug development company focused on severe lung diseases

July 3, 2018 Vicore Pharma Holding AB (publ) ("Vicore" or "The Company") has entered into an agreement to acquire INIM Pharma AB ("INIM"), a Swedish biopharmaceutical company deve...
Read more